

Trials Current as of 15th January 2018

TUMOUR	TRIAL/AGENT: PHASE 1	KEY POINTS	PI	SC
Any	SHR1316-002 PDL1 IV 4 weekly	Advanced Solid Tumors	BM	CB
Solid Tumour	AK104-101	Phase 1A dose escalation of AK104-101 - PD1/PDL1 and CTLA4 inhibitor for advanced solid tumours. Optional biopsy. 2 weekly IV	BM	CAH
Solid Tumour	BGB 900-101	Expansion for solid tumours with BGB 333PDL1 and BGB A317 PD1 combo for advance solid tumours optional biopsy.	BM	CAH
SCLC	BGB-A317 / 290:PD1 inh plus PARP inh	Max 2L prior chemo	BM	PM
RCC	BMS IDO: IDO inhib + Nivolumab	Paired biopsy	BM	IN
RCC	Corvus: Adenosine antag +/- PDL1 (atezolizumab)	Paired biopsies, prior I-O permitted	BM	IN
Urothelial	BGB-A317 / 290:PD1 inh plus PARP inh	Max 2 lines prior chemo	BM	PM
Prostate	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD	BM	PM
Prostate	ES414 antibody mCRPC	Continuous infusion via CADD	AA	LD
Prostate	GSK525762 + abiraterone or enzalutamide mCRPC daily oral	1 biopsy W3	AA	LD
Melanoma	BMS IDO inhib + nivolumab	Paired biopsies, prior I-O permitted	BM	IN
HNSCC	BMS IDO: inhib + nivolumab	Paired biopsies, prior I-O permitted (2 slots remain)	BM	IN
TNBC	Corvus: Adenosine antag +/- PDL1 (atezolizumab)	Paired biopsies, prior I-O permitted, only PDL1 (4 slots remain)	BM	IN
TNBC	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD	BM	PM
TNBC	T-Vec-20140299	Administration by image guided injection into liver lesion, additional liver biopsy W1, 7 & 16	BM	CAH
Ovarian	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD, platinum sensitive	BM	PM
Ovarian	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA WT, platinum sensitive	BM	PM
Oesophageal& GOJ	APROC: APR246 plus 5FU/cisplatin	Platinum refractory only, ≤2 lines chemo in met setting	BM	CB
Gastric & GOJ	BGB-A317 / 290:PD1 inh plus PARP inh	Max 2 lines prior therapy	BM	PM
Pancreas	BGB-A317 / 290:PD1 inh plus PARP inh	Max 1 L prior chemo; BRCA mut if platinum naïve, not if exposed	BM	PM
Colorectal with liver metastases	T-Vec-20140299	Administration by image guided injection into liver lesion, additional liver biopsy W1, 7 & 16	BM	CAH

Irina A: 22018 Cheryl-Ann H:22788 Penny M: 22429 Chris B: 22393 Louise D: 22921 Chris P: 22415 Laima M: 22924 Lindsay G: 22419 Steph K: 22017 Katie Cao: 22019
Kim B: 22024 Linda G: 22020 Isabelle N: 22025

Please note: Katie Cao is replacement coordinator for Lisa Robinson and Steph Kaladis is replacement coordinator for Shelley Firth

Tumour	Trial	TRIAL/AGENT: PHASE 2/3	PI	SC
HNSCC- rec/met	BMS study	Open Label, Randomized, Study of Nivolumab + Ipilimumab Vs Extreme Study Regimen as a 1 st line therapy	DD	LM
NSCLC ALK+	ALTA	Open-Label Study of Brigatinib (AP6113) vs Crizotinib	PB	LM
NSCLC	BR.31	Double blind placebo adjuvant MEDI4736 in completely resected NSCLC	PB	LM
NSCLC	Fraction lung	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced NSCLC	BM	LT
NSCLC	OSCILLATE	Ph 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced NSCLC	PB	LT
Mesothelioma	CA209-743	Nivolumab + Ipilimumab vs Pemetrexed with Cisplatin or Carboplatin as 1st line therapy	PB	LM
mRCC	Fraction renal	Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced RCC	DP	IA
mRCC	Medimmune renal	A Ph 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) with Durva vs Nivo Monotherapy in mRCC	AA	LG
Bladder TCC	Javelin Bladder	Avelumab + supportive care vs best supportive care alone in patients who did not progress after 1st line therapy	DP	IA
Prostate hi risk	Embark	Enzalutamide + leuprolide, enzalutamide monotherapy + placebo in non-metastatic prostate ca progressing after definitive therapy	DP	CP
Prostate	EH prostate biology	Studies of prostate cancer biology	AA	NN
Prostate	PROfound	Ph I/*II study of Olaparib in MCRPC patient with genetic mutation	AA	IA
Prostate	IMbassador	Ph III rand trial of enzalutamide +/- atezo in patients with MCRPC after failure of androgen synthesis inhibitor after taxane	DP	SK
Prostate	IPATential	Ph III rand trial of abi +/- ipatasertib placebo controlled in asymptomatic or mildly symptomatic MCRPC	DP	LG
Prostate	MDV3800-06 MCRPC	Ph 2 Open-Label 2 arm st Talazoparib in DNA Repair Defects & MCRPC previous Taxane-Based Chemotherapy and Progressed on abi or enza	AA	IA
Prostate	ICE-PAC	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC)	AA	LG
CRC Stage II	Dynamic	Circulating tumour DNA analysis informing adjuvant chemotherapy	MH	SK
Adj CRC	ASCOLT	Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers	AS	SK
mBRAF mCRC	ARRAY (BEACON)	Open-Label 3-arm study; Encorafenib + Cetuxomab Bimetinib vs Irinotecan/Cetuximab or FOLFIRI/Cetuximab	AS	SK
GI NEC	NABNEC	Randomised Ph II: nab-paclitaxel + carboplatin as 1 st line treatment	BM	KC
Adj Gastrooes	Checkmate G/O	Nivolumab or placebo in patients with resected lower esophageal or GOJ	AS	SK
Met Gastrooes	INTEGRATE II	Double-blind Placebo-controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer	AS	KC
Met Gastrooes	MSD Gastric	Pembrolizumab versus Paclitaxel after progression on 1 st line therapy with platinum and fluoropyrimidine	AS	KC
Pancreas	Halo	RDB placebo-contr PEGylated recombinant hyaluronidase (PEGPH20) + nab-Paclitaxel + gemcitabine in hyaluron-high 1 st L	MH	KC
Pancreas	PanCo	Ph III study of Oncosil in untreated metastatic or locally pancreatic ca	MH	KB
Endometrial	Millenium Endometrial	Ph2 MLN0128(dual TORC1/2inhibitor), MLN0128+MLN1117(P13Ka Inhibitor), weekly paclitaxel or weekly paclitaxel + MLN0128 in advanced, recurrent or persistent EC	GG	KB
Endometrial	PHAEDRA	Ph II trial of Durvalumab in advanced endometrial cancer	GG	KB
Ovarian	DYNAMIC	Circulating Tumour DNA	GG	SK
TNBC	IMPassion	Neoadj Chemotherapy and Immunotherapy	DD	FB
Breast HER 2+	Tabitha	Treatment of advanced breast ca in the HER-pos australian patient	MH	
Glioblastoma	Vertu	R Ph II veliparib + RT with adjuvant TMZ + veliparib vs RT+TMZ then TMZ in newly diagnosed GBM with unmethylated (MGMT)	RF	IA
Bone Metastases	TANGO bone pain	Placebo controlled, analgesic subcut Tanezumab (PF-04383119) for cancer pain due to bone mets receiving background opioid	MF	SK
Cough	Methadone Cough	Efficacy of low dose methadone as an antitussive for patients with malignancy	MF	
Medical Oncology	iPREDICT	INTEGRATION OF GENOMIC SEQUENCING INTO CLINICAL CARE: A DEMONSTRATION EVALUATION.	BM	LT
RARE CANCERS		A PHASE II CLINICAL TRIAL EVALUATING IPI & NIVO FOR THE TREATMENT OF RARE GASTROINTESTINAL, NEURO-ENDOCRINE AND GYNAECOLOGICAL CANCERS	BM	LG